01—Abstract
Summary
Summary of the 8-K filed February 8, 2008. Cited figures are marked; the original filing is the authoritative source.
Ecolab Inc. (ECL) filed an 8-K on February 7, 2008, reporting on a significant financing event.
On February 5, 2008, the company entered into an underwriting agreement to issue and sell $250 milliona in aggregate principal amount of 4.875% Notes due 2015. This debt issuance is a key development for investors to note, as it impacts the company's capital structure and financial obligations. The net proceeds from this offering are intended to be used for repaying commercial paper borrowings, which were previously used for general corporate purposes and to finance acquisitions of Microtek Medical Holdings, Inc. and Ecovation, Inc. This indicates that Ecolab is managing its short-term debt and funding strategic growth initiatives through this medium-term debt issuance.
02—Key points
Key Highlights
- Ecolab Inc. issued $250 million of 4.875% Notes due February 15, 2015.
- The notes were issued under an underwriting agreement with Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, and JP Morgan Securities Inc.
- Proceeds are earmarked for repaying commercial paper and financing recent acquisitions (Microtek Medical Holdings, Inc. and Ecovation, Inc.).
- The notes are unsecured and unsubordinated, ranking equally with existing and future unsecured and unsubordinated debt.
- The indenture includes provisions that limit the company's ability to incur certain liens or sell substantially all assets.
- A change of control event, coupled with a downgrade below investment grade by both Moody's and S&P, triggers an offer to repurchase the notes at 101% of par.
- The offering was made under an effective automatic shelf registration statement filed on February 5, 2008.
03—Questions
Frequently Asked Questions
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report Ecolab Inc.'s entry into a material definitive agreement for the issuance and sale of $250 million of 4.875% Notes due 2015.
How will Ecolab use the proceeds from the note issuance?
Ecolab expects to use the net proceeds to repay a portion of its commercial paper borrowings (used for general corporate and working capital purposes) and to finance a part of its acquisitions of Microtek Medical Holdings, Inc. and Ecovation, Inc.
What are the key terms of the new notes?
The notes bear a 4.875% annual interest rate, payable semi-annually on February 15 and August 15, with the first payment on August 15, 2008. They mature on February 15, 2015. The company can redeem the notes prior to maturity under specified conditions, including a make-whole premium. The notes are unsecured and unsubordinated.
Are there any specific covenants or protections for noteholders?
Yes, the indenture limits the company's ability to incur certain liens or sell substantially all of its assets. Additionally, if a change of control occurs and the notes are downgraded below investment grade by both Moody's and S&P within a specified period, Ecolab must offer to repurchase the notes at 101% of their principal amount plus accrued interest.
04—Continue